HB Wealth Management LLC Purchases 13,249 Shares of Gilead Sciences, Inc. $GILD

HB Wealth Management LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 39.0% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 47,188 shares of the biopharmaceutical company’s stock after buying an additional 13,249 shares during the period. HB Wealth Management LLC’s holdings in Gilead Sciences were worth $5,238,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GoalVest Advisory LLC boosted its stake in shares of Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the last quarter. Harbor Asset Planning Inc. purchased a new stake in Gilead Sciences in the 2nd quarter worth approximately $27,000. Putney Financial Group LLC increased its stake in shares of Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares in the last quarter. Howard Hughes Medical Institute bought a new stake in Gilead Sciences during the second quarter valued at about $30,000. Finally, Kilter Group LLC bought a new stake in Gilead Sciences during the 2nd quarter valued at approximately $33,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Mizuho lifted their price target on shares of Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a report on Friday, November 21st. BMO Capital Markets set a $135.00 price target on Gilead Sciences in a research report on Tuesday, November 25th. TD Cowen boosted their price objective on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Rothschild & Co Redburn increased their price target on Gilead Sciences from $143.00 to $153.00 in a report on Monday, November 10th. Finally, Wall Street Zen upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 3rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $133.20.

Insider Buying and Selling

In other Gilead Sciences news, Director Kelly A. Kramer sold 2,805 shares of Gilead Sciences stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.10, for a total value of $356,515.50. Following the transaction, the director directly owned 1,339 shares of the company’s stock, valued at approximately $170,186.90. The trade was a 67.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the transaction, the director directly owned 8,920 shares in the company, valued at approximately $1,115,713.60. The trade was a 35.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 136,257 shares of company stock valued at $16,855,192 over the last quarter. Insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Up 0.4%

Shares of Gilead Sciences stock opened at $121.10 on Friday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The firm’s 50-day moving average is $123.27 and its two-hundred day moving average is $117.51. Gilead Sciences, Inc. has a 1 year low of $88.57 and a 1 year high of $128.70. The stock has a market cap of $150.25 billion, a price-to-earnings ratio of 18.78, a PEG ratio of 0.64 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. Gilead Sciences’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.